Literature DB >> 9121257

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups.

T Poynard1, P Bedossa, P Opolon.   

Abstract

BACKGROUND: Our aim was to assess the natural history of liver fibrosis progression in hepatitis C and the factors associated with this progression.
METHODS: We recruited 2235 patients from the Observatoire de l'Hépatite C (OBSVIRC) population, the Cohorte Hépatite C Pitié-Salpétrière (DOSVIRC) population, and the original METAVIR population. All the patients had a biopsy sample compatible with chronic hepatitis C as assessed by the METAVIR scoring system (grades the stage of fibrosis on a five-point scale, F0 = no fibrosis, F4 = cirrhosis, and histological activity on a four-point scale, A0 = no activity, A3 = severe activity). No patient had received interferon treatment before the liver biopsy sample was obtained. We assessed the effect of nine factors on fibrosis progression: age at biopsy; estimated duration of infection; sex; age at infection; alcohol consumption; hepatitis C virus C (HCV) genotype; HCV viraemia; cause of infection; and histological activity grade. We defined fibrosis progression per year as the ratio between fibrosis stage in METAVIR units and the duration of infection (1 unit = one stage, 4 units = cirrhosis).
FINDINGS: The median rate of fibrosis progression per year was 0.133 fibrosis unit (95% CI 0.125-0.143), which was similar to the estimates from previous studies (0.146 to 0.154). Three independent factors were associated with an increased rate of fibrosis progression: age at infection older than 40 years, daily alcohol consumption of 50 g or more, and male sex. There was no association between fibrosis progression and HCV genotype. The median estimated duration of infection for progression to cirrhosis was 30 years (28-32), ranging from 13 years in men infected after the age of 40 to 42 years in women who did not drink alcohol and were infected before the age of 40. Without treatment, 377 (33%) patients had an expected median time to cirrhosis of less than 20 years, and 356 (31%) will never progress to cirrhosis or will not progress for at least 50 years.
INTERPRETATION: The host factors of ageing, alcohol consumption, and male sex have a stronger association with fibrosis progression than virological factors in HCV infection.

Entities:  

Mesh:

Year:  1997        PMID: 9121257     DOI: 10.1016/s0140-6736(96)07642-8

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  610 in total

1.  Indications for referral and assessment in adult liver transplantation: a clinical guideline. British Society of Gastroenterology.

Authors:  J Devlin; J O'Grady
Journal:  Gut       Date:  1999-12       Impact factor: 23.059

Review 2.  Hepatitis C and liver transplantation.

Authors:  M Berenguer; T L Wright
Journal:  Gut       Date:  1999-08       Impact factor: 23.059

Review 3.  Hepatitis C: universal or selective screening?

Authors:  R P Brettle
Journal:  Sex Transm Infect       Date:  1998-10       Impact factor: 3.519

Review 4.  Mechanisms of immune escape in viral hepatitis.

Authors:  W Rosenberg
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

Review 5.  Recent advances: hepatology.

Authors:  M McCarthy; M L Wilkinson
Journal:  BMJ       Date:  1999-05-08

6.  The science, economics, and effectiveness of combination therapy for hepatitis C.

Authors:  G Dusheiko; E Barnes; G Webster; S Whalley
Journal:  Gut       Date:  2000-08       Impact factor: 23.059

7.  Heavy drinking greatly increases the risk of cirrhosis in patients with HCV hepatitis.

Authors:  C P Day
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

8.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

9.  Detection of novel biomarkers of liver cirrhosis by proteomic analysis.

Authors:  Christian Mölleken; Barbara Sitek; Corinna Henkel; Gereon Poschmann; Bence Sipos; Sebastian Wiese; Bettina Warscheid; Christoph Broelsch; Markus Reiser; Scott L Friedman; Ida Tornøe; Anders Schlosser; Günter Klöppel; Wolff Schmiegel; Helmut E Meyer; Uffe Holmskov; Kai Stühler
Journal:  Hepatology       Date:  2009-04       Impact factor: 17.425

10.  Alpha-fetoprotein before and after pegylated interferon therapy for predicting hepatocellular carcinoma development.

Authors:  Yasuto Takeuchi; Fusao Ikeda; Toshiya Osawa; Yasuyuki Araki; Kouichi Takaguchi; Youichi Morimoto; Noriaki Hashimoto; Kousaku Sakaguchi; Tatsuro Sakata; Masaharu Ando; Yasuhiro Makino; Shuji Matsumura; Hiroki Takayama; Hiroyuki Seki; Shintarou Nanba; Yuki Moritou; Tetsuya Yasunaka; Hideki Ohnishi; Akinobu Takaki; Kazuhiro Nouso; Yoshiaki Iwasaki; Kazuhide Yamamoto
Journal:  World J Hepatol       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.